Michael Schamroth is Director at BIOSPECIFICS TECHNOLOGIES CORP (BSTC). They have made 5 open-market trades across 2 companies since 2008, most recently 2020-12-02.
CIK 0001375385
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BSTC | SELL | 2014-11-24 | 2014-11-25 | $39.36 | $177K | -9.3% | -6.3% | -6.3% |
| BSTC | SELL | 2014-11-19 | 2014-11-21 | $39.10 | $196K | -9.3% | -6.3% | -6.3% |
| BSTC | SELL | 2014-11-17 | 2014-11-19 | $39.00 | $12K | -9.3% | -6.3% | -6.3% |
| BSTC | SELL | 2014-11-12 | 2014-11-14 | $39.20 | $204K | -9.3% | -6.3% | -6.3% |
| BSTC.PK | SELL | 2008-03-17 | 2008-03-26 | $11.90 | $595K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.